Prasugrel versus Clopidogrel for Acute Coronary Syndromes without Revascularization

Roe, Matthew T., Armstrong, Paul W., Fox, Keith A.A., White, Harvey D., Prabhakaran, Dorairaj, Goodman, Shaun G., Cornel, Jan H., Bhatt, Deepak L., Clemmensen, Peter, Martinez, Felipe, Ardissino, Diego, Nicolau, Jose C., Boden, William E., Gurbel, Paul A., Ruzyllo, Witold, Dalby, Anthony J., McGuire, Darren K., Leiva-Pons, Jose L., Parkhomenko, Alexander, Gottlieb, Shmuel, Topacio, Gracita O., Hamm, Christian, Pavlides, Gregory, Goudev, Assen R., Oto, Ali, Tseng, Chuen-Den, Merkely, Bela, Gasparovic, Vladimir, Corbalan, Ramon, Cinteză, Mircea, McLendon, R. Craig, Winters, Kenneth J., Brown, Eileen B., Lokhnygina, Yuliya, Aylward, Philip E., Huber, Kurt, Hochman, Judith S., Ohman, E. Magnus·2012·New England Journal of Medicine
DOI 10.1056/nejmoa1205512

Cited by (873)

Items 501–600 of 873

  1. Efficacy and Safety of Potent Oral P2Y12 Inhibitors in Medically Managed ACS Patients: a Meta-analysis
    Sicong Ma, Zhiguo Li, Peng Yu, Haixu Song, Zaixin Jiang, Yi Li, Yaling Han · 2020 · Cardiovascular Drugs and Therapy
  2. Neurological complications of cardiovascular drugs
    Michael A. Kelly · 2021 · Handbook of clinical neurology
  3. Antithrombotic strategies in elderly patients with acute coronary syndrome
    Jean‐Guillaume Dillinger, Marc Laine, Sara Bouajila, Franck F. Paganelli, Patrick Henry, Laurent Bonello · 2021 · Archives of cardiovascular diseases
  4. Determinants of long-term dual antiplatelet therapy use in post myocardial infarction patients: Insights from the TIGRIS registry
    Juan J. Russo, Andrew Tze-Kay Yan, Stuart Pocock, David B. Brieger, Ruth Owen, Karolina Andersson Sundell, Akshay Bagai, Christopher Bull Granger, Mauricio G. Cohen, Satoshi Yasuda et al. · 2021 · Journal of Cardiology
  5. Antithrombotika und Antihämorrhagika
    Lutz Hein, Hans Wille · 2016 · Springer eBooks
  6. Antithrombotic Treatment in Coronary Artery Disease
    Gerasimos Siasos, Vasiliki Tsigkou, Evanthia Bletsa, Panagiota K. Stampouloglou, Evangelos K. Oikonomou, Konstantinos I. Kalogeras, Ουρανία Κατσαρού, Theodoros Pesiridis, Μanolis Vavuranakis, Dimitris Tousoulis · 2023 · Current Pharmaceutical Design
  7. Frailty in acute coronary syndromes. A systematic review and narrative synthesis of frailty assessment tools and interventions from randomised controlled trials
    Thomas Chad, Marinos Koulouroudias, Georgia R. Layton, Oluwatomini A. Fashina, Shirley Sze, Marius Roman, Gavin James Murphy · 2024 · International Journal of Cardiology
  8. Measuring Platelet Reactivity after Clopidogrel-Has it Reached the End of the Road?
    Cheuk Kit Wong · 2013 · Cardiovascular Pharmacology Open Access
  9. Update on oral antithrombotic therapy for secondary prevention following non-ST segment elevation myocardial infarction
    Yongwhi Park, Francesco Franchi, Fabiana Rollini, Dominick Joseph Angiolillo · 2015 · Trends in Cardiovascular Medicine
  10. Platelet reactivity tests for assessing antiplatelet drug response: what the clinician needs to know
    Sabine Steiner, Deddo Moertl · 2013 · Expert Review of Cardiovascular Therapy
  11. Key Advances in Clinical Cardiology
    Michael Connolly, Ian B A Menown · 2013 · Advances in Therapy
  12. Fatal Sepsis and Systemic Inflammatory Response Syndrome After Off-Label Prasugrel
    Victor L. Serebruany, Nodar N Kipshidze, Першуков Игорь Викторович, Wiktor Kuliczkowski, Judy Carnes, Dan Atar · 2013 · American Journal of Therapeutics
  13. Subgroup analyses with special reference to the effect of antiplatelet agents in acute coronary syndromes
    Doron Aronson · 2014 · Thrombosis and Haemostasis
  14. Evidence for compliance with long-term medication: a systematic review of randomised controlled trials
    Michelle A. King, Rebecca Pryce · 2013 · International Journal of Clinical Pharmacy
  15. Comparison of new adenosine diphosphate receptor antagonists with clopidogrel in patients with coronary artery disease: a meta-analysis
    Jong Seok Bae, Jae‐Sik Jang · 2014 · Heart and Vessels
  16. Antithrombotics in atrial fibrillation and coronary disease
    Poonam Velagapudi, Mohit K. Turagam, Harsh Agrawal, Mayank Mittal, Abraham G. Kocheril, Kul B. Aggarwal · 2014 · Expert Review of Cardiovascular Therapy
  17. Dual Antiplatelet Therapy Dilemmas: Duration and Choice of Antiplatelets in Acute Coronary Syndromes
    Matthew Ian Tomey, Roxana Mehran · 2013 · Current Cardiology Reports
  18. Update on Ischemic Heart Disease and Critical Care Cardiology
    Francisco R. Marín, Óscar Dı́az-Castro, Juan M. Ruiz-Nodar, Bernardo García de la Villa, Alessandro Sionís, Javier López, Antonio Fernández‐Ortíz, Manuel Martínez‐Sellés · 2014 · Revista Española de Cardiología (English Edition)
  19. Pooled analysis of adverse event collection from 4 acute coronary syndrome trials
    André Zimerman, Renato D. Lópes, Amanda Stebbins, Patrícia O. Guimarães, Ghazala Haque, Chiara Melloni, Kathleen M. Trollinger, Stefan Karl James, John Hunter Alexander, Pierluigi Tricoci et al. · 2016 · American Heart Journal
  20. Effect of Potent P2Y12 Inhibitors on Ventricular Arrhythmias and Cardiac Dysfunction in Coronary Artery Disease: A Systematic Review and Meta-Analysis
    Chunmei Wang, Guanqi Zhao, Xiao Wang, Shaoping Nie · 2018 · BioMed Research International
  21. Update on Ischemic Heart Disease and Critical Care Cardiology
    Javier Jiménez‐Candil, Óscar Dı́az-Castro, José A. Barrabés, Bernardo García de la Villa, Vicente Bodí Peris, Ramón López‐Palop, Antonio Fernández‐Ortíz, Manuel Martínez‐Sellés · 2013 · Revista Española de Cardiología (English Edition)
  22. High Rates of Recurrent Revascularization in Acute Limb Ischemia – A National Surgical Quality Improvement Program Study
    Ryan Gupta, Sammy Siada, Michael R. Bronsert, Mohammed H. Al-Musawi, Mark R. Nehler, Jeniann A. Yi · 2022 · Annals of Vascular Surgery
  23. Contemporary Trends and Outcomes Associated With the Preprocedural Use of Oral P2Y12 Inhibitors in Patients Undergoing Percutaneous Coronary Intervention: Insights From the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2).
    Devraj Sukul, Milan Seth, Simon R. Dixon, Akshay K. Khandelwal, Thomas A. Lalonde, Hitinder Singh Gurm · 2017 · PubMed
  24. Oral antiplatelets in primary and secondary prevention of myocardial infarction: a review
    Rajkumar Prakashbhai Doshi, Abhishek Vadher, Priyam Mithawala, Priyank Shah · 2018 · Irish Journal of Medical Science (1971 -)
  25. Associations between use of prasugrel vs clopidogrel and outcomes by type of acute coronary syndrome: an analysis from the PROMETHEUS registry
    Zhen Ge, Usman Baber, Bimmer E.P.M. Claessen, Jaya Chandrasekhar, Rishi Chandiramani, Shawn X. Li, Samantha Sartori, Annapoorna Subhash Kini, Sunil V. Rao, Sandra A. Weiss et al. · 2019 · Journal of Thrombosis and Thrombolysis
  26. Secondary Prevention with Antithrombotic Therapies in Stable Ischemic Heart Disease Patients: a Review
    Aaron Shanker, Vivek Bhupathi · 2019 · Current Cardiology Reports
  27. Duale Plättchenhemmung in der Intensivmedizin
    Jolanta Maria Siller-Matula, Georg Delle Karth · 2014 · Medizinische Klinik - Intensivmedizin und Notfallmedizin
  28. Cost–effectiveness of ticagrelor in acute coronary syndromes
    Martin Henriksson, Magnus Janzon · 2013 · Expert Review of Pharmacoeconomics & Outcomes Research
  29. Antiplatelet Treatment in the Secondary Prevention of Coronary and Cerebrovascular Disease
    Ioannis V. Ntalas, Haralampos J. Milionis, Anastazia A. Kei, Kallirroi I. Kalantzi, John A. Goudevenos · 2013 · Angiology
  30. Current Antithrombotic Therapy in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Interventions
    Gabriele Pesarini, Sara Ariotti · 2011 · Interventional Cardiology Reviews Research Resources
  31. The Softer Side of Bleeding
    Harold L. Dauerman · 2013 · Journal of the American College of Cardiology
  32. Current practice on the management of acute coronary syndrome in China
    Tsung O. Cheng, Dong Hui Zhao · 2013 · International Journal of Cardiology
  33. We Need to Do Better for Patients With Non–ST-Segment Elevation Acute Coronary Syndrome Who Are Managed Without Revascularization∗
    E. Magnus Ohman, Ralf E. Harskamp · 2014 · Journal of the American College of Cardiology
  34. The enigmatic search for optimal DAPT duration
    Paul A. Gurbel, Elisabeth Mahla, Udaya S. Tantry · 2013 · European Heart Journal
  35. Nuevas evidencias sobre la antiagregación para el síndrome coronario agudo sin elevación del ST
    Alberto Cecconi, David Vivas, Antonio Fernández‐Ortíz · 2014 · Revista Española de Cardiología Suplementos
  36. Ticagrelor Paradox: Systematic Review and Network Meta‐Analysis
    Atsuyuki Watanabe, Tadao Aikawa, Yoshihisa Miyamoto, Hiroki A. Ueyama, Tomohiro Fujisaki, Satoshi Shoji, Kaveh Hosseini, Leandro N. Slipczuk, Αlexandros Briasoulis, Polydoros Ν. Kampaktsis et al. · 2025 · Journal of the American Heart Association
  37. Nuevos antiagregantes plaquetarios en cardiopatía isquémica
    Antonio Tello‐Montoliu, Eva Jover, Mariano Valdés · 2014 · Medicina Clínica
  38. Optimicemos el uso de los nuevos antiagregantes orales. Propuesta de protocolos comunes en el síndrome coronario agudo
    Inmaculada Roldán‐Rabadán, Antonio Tello‐Montoliu, Francisco R. Marín · 2014 · Revista Española de Cardiología Suplementos
  39. Prasugrel and ticagrelor
    Nuccia Morici, Paola Colombo, Antonio Mafrici, Jacopo Oreglia, Silvio Klugmann, Stefano Savonitto · 2014 · Journal of Cardiovascular Medicine
  40. Early vs. Delayed Initiation of Treatment With P2Y12 Inhibitors in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
    Lourdes Vicent, Carlos Diaz‐Arocutipa, Giuseppe Tarantini, Marco Mojoli, Adrián Vladimir Hernández, Héctor Bueno · 2022 · Frontiers in Cardiovascular Medicine
  41. Incidence and predictors of intracranial bleeding after coronary artery bypass graft surgery
    Ju Hyeon Kim, Pil Hyung Lee, Ho Jin Kim, Joon Bum Kim, Sojeong Park, Dae‐Sung Kyoung, Soo‐Jin Kang, Seung‐Whan Lee, Young‐Hak Kim, Cheol Whan Lee et al. · 2022 · Frontiers in Cardiovascular Medicine
  42. Comprehensive comparative efficacy and safety of potent P2Y12 inhibitors in patients undergoing coronary intervention: A systematic review and meta-analysis
    Chien-Lung Huang, Tien‐Ping Tsao, Wei‐Hsian Yin, Wen-Bin Huang, Hsu-Lung Jen, Chang‐Chyi Lin, Chung‐Yi Chang, Ching‐Hwa Hsu · 2024 · IJC Heart & Vasculature
  43. Safety and efficacy of P2Y12 inhibitors in acute coronary syndromes patients with KDIGO stage IV-V renal disfunction not on dialysis: a subanalysis of the CORALYS registry
    Federico Giacobbe, Francesco Bruno, Giuseppe Giannino, Filippo Angelini, Stefano Siliano, Arianna Morena, Alessandra Truffa Giachet, Emanuele Sagazio, Fabrizio D’Ascenzo, Federico Marchini et al. · 2025 · International Journal of Cardiology
  44. Diretriz de Síndrome Coronariana Crônica – 2025
    Luíz Antonio Machado César, Luís Henrique Wolff Gowdak, Ricardo Pavanello, João Fernando Monteiro Ferreira, Bruno Mahler Mioto, Nilson Tavares Poppi, Cledson Jatiniel Lima Mendonça, Adenalva Lima de Souza Beck, Adriana Soares Xavier de Brito, Alexandre Abizaid et al. · 2025 · Arquivos Brasileiros de Cardiologia
  45. Antiagregación: resistencia a fármacos tradicionales y papel de los nuevos antiplaquetarios
    Hugo del Castillo-Carnevali, Vivencio Barrios, José Luis Zamorano Gómez · 2013 · Medicina Clínica
  46. Strategies to Reduce Bleeding Risk in Acute Coronary Syndromes and Percutaneous Coronary Intervention: New and Emerging Pharmacotherapeutic Considerations
    James C. Coons, Taylor J. Miller · 2014 · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
  47. P2Y12-receptor-inhibiting antiplatelet strategies in acute coronary syndromes
    Kurt Huber, Thomas Höchtl · 2013 · Hämostaseologie
  48. P2Y12 antagonists in non-ST-segment elevation acute coronary syndromes: latest evidence and optimal use
    Nicholas B. Norgard, James J. DiNicolantonio · 2015 · Therapeutic Advances in Chronic Disease
  49. Cancer after intense and prolonged antiplatelet therapies – fact or fiction?
    Raffaele De Caterina · 2015 · Thrombosis and Haemostasis
  50. Prasugrel hydrochloride for the treatment of acute coronary syndrome patients
    Ashan Gunarathne, Shahana Hussain, Anthony Gershlick · 2016 · Expert Review of Cardiovascular Therapy
  51. Optimal duration of dual antiplatelet therapy after acute coronary syndromes and coronary stenting
    Alon Eisen, Deepak L. Bhatt · 2016 · Heart
  52. Use of Alternative Antiplatelet Agents for Clopidogrel Hypersensitivity
    Ayesha Ather, Craig James Beavers · 2019 · Current Vascular Pharmacology
  53. Clopidogrel or prasugrel reduces mortality and lessens cardiovascular damage from acute myocardial infarction in hypercholesterolemic male rats
    Hala M.F. Mohammad, Samy Makary, Hoda Atef, Mohamed El‐Sherbiny, Hebatallah Husseini Atteia, Gehan A. Ibrahim, Abdelaty Shawky Mohamed, Sawsan A. Zaitone · 2020 · Life Sciences
  54. Novel Antiplatelet Agents in Cardiovascular Medicine
    Rahil Rafeedheen, Kevin P. Bliden, Fang Liu, Udaya S. Tantry, Paul Alfred Gurbel · 2015 · Current Treatment Options in Cardiovascular Medicine
  55. Pharmacokinetic evaluation of prasugrel for the treatment of myocardial infarction
    James C. Coons, Nicholas C. Schwier, Justin R. Harris, Amy L. Seybert · 2014 · Expert Opinion on Drug Metabolism & Toxicology
  56. Prasugrel hydrochloride for the treatment of acute coronary syndromes
    Thibault Lhermusier, Ron Waksman · 2015 · Expert Opinion on Pharmacotherapy
  57. New antiplatelet drugs for acute coronary syndrome
    Praveen Indraratna, Christoper Cao · 2014 · Australian Prescriber
  58. The PARTHENON Clinical Development Program: the Role of Ticagrelor in Patients with Atherothrombotic Disease
    Paul P. Dobesh, Manesh R. Patel · 2017 · Cardiovascular Drugs and Therapy
  59. Early discontinuation of prasugrel or clopidogrel in acute coronary syndromes
    Andrew Tze-Kay Yan, Matthew T. Roe, Megan Lee Neely, Derek D. Cyr, Harvey Douglas White, Keith A.A. Fox, Dorairaj Prabhakaran, Paul W. Armstrong, E. Magnus Ohman, Shaun G. Goodman · 2018 · Coronary Artery Disease
  60. Identification of Potential Biological Factors Affecting the Treatment of Ticagrelor After Percutaneous Coronary Intervention in the Chinese Population
    Dongdong Yuan, Xiangfen Shi, Liping Guo, Gaobiao Wang, Hanjuan Zhang, Yuling Yang, Yujie Zhao, Didi Sun · 2022 · Pharmacogenomics and Personalized Medicine
  61. Is it Time to Repair a Fairly Fast SAAB Convertible? Testing an Evidence-based Mnemonic for the Secondary Prevention of Cardiovascular Disease
    Jialiang Chin, Jordan Fulcher, Alicia Josephine Jenkins, ANTHONY C. KEECH · 2014 · Heart Lung and Circulation
  62. Genotype- and phenotype-directed antiplatelet therapy selection in patients with acute coronary syndromes
    Sahar J. Ismail, Yee Ming Lee, Meet Patel, Julio D. Duarte, Amer Kasim Ardati · 2014 · Expert Review of Cardiovascular Therapy
  63. Health-related quality of life outcomes with prasugrel among medically managed non–ST-segment elevation acute coronary syndrome patients: Insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY ACS) trial
    Padma Kaul, E. Magnus Ohman, J. David Knight, Kevin Joseph Anstrom, Matthew T. Roe, William E. Boden, Judith S. Hochman, Vladimir Gašparović, Paul W. Armstrong, Patrick L. McCollam et al. · 2016 · American Heart Journal
  64. Major predictors of stent thrombosis in patients with acute coronary syndrome following transcutaneous coronary intervention who received different double antiplatelet therapy
    E. S. Korotaeva, L. Yu. Koroleva, Г. В. Ковалева, Е. А. Кузьменко, В. П. Носов · 2018 · Kardiologiia
  65. P2Y12 Antagonists
    Marco Cattaneo · 2019 · Elsevier eBooks
  66. Substitutes of Prescription Medicines - A Review of Concerns Relevant to Doctors and Patients
    Jayant Kumar Kairi · 2017 · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH
  67. Potential Benefits of Ticagrelor beyond Platelet Inhibition
    Dennis Winston T. Nilsen · 2013 · Cardiology
  68. Prasugrel
    Victor L. Serebruany, Dan Atar · 2013 · Circulation Cardiovascular Quality and Outcomes
  69. Time for a paradigm shift? Making the case for tailored selection of antiplatelet therapy
    Michelle L. O’Donoghue, Nicholas Marston · 2022 · European Heart Journal
  70. Optimizing selection of P2Y 12 inhibiting therapy: clopidogrel, prasugrel or ticagrelor
    Mattía Galli, Beatrice Simeone, Felice Gragnano, Domenico D’Amario, Gianmarco Sarto, Giacomo Frati, Ernesto Greco, Paolo Calabrò, Sebastiano Sciarretta, Roxana Mehran et al. · 2025 · Expert Opinion on Pharmacotherapy
  71. Antiplatelet Therapy in the Management of Atherosclerotic Cardiovascular Disease: 2026 ACC Scientific Statement
    Dharam J. Kumbhani, Charles Michael Gibson, Scott Kinlay, Eric David Peterson, Amy West Pollak, Jacqueline E. Tamis‐Holland, Freek W.A. Verheugt · 2026 · Journal of the American College of Cardiology
  72. Management of antithrombotic therapy in patients with atrial fibrillation and acute coronary syndromes
    Călin Pop, Diana Ţînţ, Antoniu Octavian Petriş · 2021 · Reviews in Cardiovascular Medicine
  73. Pretreatment With P2Y12 Inhibitors in Contemporary Practice
    Mandeep Singh, Marco Valgimigli · 2025 · Mayo Clinic Proceedings
  74. Efficacy and safety of low-dose prasugrel as dual antiplatelet therapy in patients with ischemic heart disease: a systematic review and network meta-analysis of randomized controlled trials
    Toshiharu Fujii, Kazushige Amano, Satoshi Kasai, Yota Kawamura, Fuminobu Yoshimachi, Yuji Ikari · 2025 · Cardiovascular Intervention and Therapeutics
  75. Effect of prior clopidogrel use on outcomes in medically managed acute coronary syndrome patients
    Chee Tang Chin, William E. Boden, Matthew T. Roe, Benjamin Neely, Megan Lee Neely, Jose Luis Leiva-Pons, Ramon L. Corbalan, Shmuel Gottlieb, Anthony J. Dalby, Paul W. Armstrong et al. · 2016 · Heart
  76. The influence of metoclopramide on pharmacokinetics and pharmacodynamics of ticagrelor in patients with unstable angina pectoris receiving concomitant treatment with morphine — a protocol of a randomized trial
    Joanna Sikora, Piotr Niezgoda, Malwina Barańska, Krzysztof Pstrągowski, Aleksandra Karczmarska‐Wódzka, Emilia Siemińska, Michał Piotr Marszałł, Grzegorz Grześk, Jacek Kubica · 2016 · Medical Research Journal
  77. Pharmacology: Inhibitors of P2Y12
    Lisa Groß, Dániel Aradi, Dirk Sibbing · 2017 · Springer eBooks
  78. Long-term dual antiplatelet therapy: pharmacological and clinical implications
    Carlo Di Mario, Alessandro Mugelli, Pasquale Perrone Filardi, Giuseppe M.C. Rosano, Francesco Rossi · 2018 · Journal of Cardiovascular Medicine
  79. Comparative efficacy and safety of oral P2Y12 inhibitors for patients with chronic kidney disease and acute coronary syndrome: a network meta-analysis
    Ioannis T. Farmakis, Ioannis Doundoulakis, Stefanos Zafeiropoulos, Areti Pagiantza, Fani Apostolidou‐Kiouti, Olga Kourti, George Kassimis, Anna‐Bettina Haidich, Haralambos I. Karvounis, George A. Giannakoulas · 2021 · Hellenic Journal of Cardiology
  80. Endogenous fibrinolysis inhibitors in acute coronary syndrome
    Baskaran Chandrasekar · 2021 · American Heart Journal Plus Cardiology Research and Practice
  81. P2Y12 Inhibitors for Non–ST-Segment Elevation Acute Coronary Syndrome: A Systematic Review and Network Meta-Analysis
    Tomohiro Fujisaki, Toshiki Kuno, Αlexandros Briasoulis, Naoki Misumida, Hisato Takagi, Azeem Latib · 2023 · Texas Heart Institute Journal
  82. Optimising pharmacotherapy for secondary prevention of non‐invasively managed acute coronary syndrome
    Peter Lindsay Thompson, Angus Thompson, Chris Judkins · 2014 · The Medical Journal of Australia
  83. Antithrombotic therapy in medically managed patients with non-ST-segment elevation acute coronary syndromes
    Paul Alfred Gurbel, Udaya S. Tantry · 2016 · Heart
  84. First 24 h in the management of non-ST segment elevation myocardial infarction
    Daljeet S. Gambhir · 2018 · European Heart Journal Supplements
  85. Outcomes of Patients Receiving Downstream Revascularization After Initial Medical Management for Non–ST-Segment Elevation Acute Coronary Syndromes (From the TRILOGY ACS Trial)
    Tomoya Timothy Hinohara, Matthew T. Roe, Harvey Douglas White, Keith A.A. Fox, Deepak L. Bhatt, Christian W. Hamm, Paul Alfred Gurbel, Philip E. Aylward, Stephen D. Wiviott, Kurt Huber et al. · 2018 · The American Journal of Cardiology
  86. Comparative efficacy and safety of oral P2Y12 inhibitors after non-ST-elevation acute coronary syndromes: a network meta-analysis
    Ioannis T. Farmakis, Stefanos Zafeiropoulos, Ioannis Doundoulakis, Areti Pagiantza, Efstratios Karagiannidis, Dimitrios V. Moysidis, Nikolaos Stalikas, George Kassimis, Lampros K. Michalis, Haralambos I. Karvounis et al. · 2022 · Open Heart
  87. Anti-aggregation therapy in patients with acute coronary syndrome — recommendations for medical emergency teams. Experts’ standpoint
    Jacek Kubica, Piotr Adamski, Przemysław Paciorek, Jerzy Robert Ładny, Zbigniew F. Kalarus, Waldemar Banasiak, Wacław Kochman, Jarosław Gorący, Beata Wożakowska−Kapłon, Eliano Pio Navarese et al. · 2017 · Kardiologia Polska
  88. Outcomes After Acute Coronary Syndrome in Patients With Diabetes Mellitus and Peripheral Artery Disease (from the TRACER, TRILOGY-ACS, APPRAISE-2, and PLATO Clinical Trials)
    Rubina Attar, Angie Wu, DANIEL M. WOJDYLA, Svend Eggert Jensen, Pontus Andell, Kenneth W. Mahaffey, Matthew T. Roe, Stefan Karl James, Lars C. Wallentin, Sreekanth Vemulapalli et al. · 2022 · The American Journal of Cardiology
  89. Recent advances in treatment of acute coronary syndromes
    Bhuvnesh Kumar Aggarwal, Venu Menon · 2013 · F1000Prime Reports
  90. Smoking and prasugrel
    Yicong Ye, Hongzhi Xie, Xiliang Zhao, Shuyang Zhang · 2013 · International Journal of Cardiology
  91. Outcomes According to Cardiac Catheterization Referral and Clopidogrel Use Among Medicare Patients With Non–ST‐Segment Elevation Myocardial Infarction Discharged Without In‐hospital Revascularization
    Connie Ng Hess, Anne S. Hellkamp, Matthew T. Roe, Laine Elliott Thomas, Benjamin M. Scirica, S. Andrew Peng, Eric David Peterson, Tracy Y. Wang · 2016 · Journal of the American Heart Association
  92. Shorter (≤6 months) vs. longer (≥12 months) dual antiplatelet therapy after second-generation drug-eluting stents implantation: a meta-analysis of randomized controlled trials
    He Huang, Ya Li, Meina Sun · 2016 · European Heart Journal Supplements
  93. Optimal Antiplatelet Therapy in ST-Segment Elevation Myocardial Infarction
    Rafael Harari, Usman Baber · 2016 · Interventional Cardiology Clinics
  94. One-year and longer dual antiplatelet therapy after an acute coronary syndrome: a Belgian position paper
    Peter Sinnaeve, Walter J. Desmet, Olivier S Descamps, Sofie Gevaert, Guy De Backer, Philippe H. Kolh, Mathias Vrolix, Philippe van de Borne, Antoine DE MEESTER, Marc J. Claeys et al. · 2017 · Acta cardiologica. Supplementum
  95. A Prospective, Randomized, Open-Label, Blinded, Endpoint Study Exploring Platelet Response to Half-Dose Prasugrel and Ticagrelor in Patients with the Acute Coronary Syndrome: HOPE-TAILOR Study
    Cai De Jin, Moo Hyun Kim, Junghee Bang, Victor L. Serebruany · 2017 · Cardiology
  96. Is there Sex-related Outcome Difference According to oral P2Y12 Inhibitors in Patients with Acute Coronary Syndromes? A Systematic Review and Meta-Analysis of 107,126 Patients
    Oliver Ian Brown, Jennifer Ann Rossington, Gill Louise Buchanan, Giuseppe Patti, Angela Hoye · 2018 · Current Vascular Pharmacology
  97. Use of Thromboelastography Platelet Mapping for Assessment of Individual Platelet Response Secondary to Oral Antiplatelet Therapy after Percutaneous Coronary Intervention: An Attempt to Start Personalized Antiplatelet Therapy in India
    Suvro Sankha Datta, Dibyendu De, Nadeem Afroz Muslim · 2021 · Journal of Cardiac Critical Care TSS
  98. Efficacy and Safety of Oral P2Y12 Inhibitors in Older Patients with Acute Coronary Syndrome: A Frequentist Network Meta-Analysis
    Izza Shahid, Muhammad Abdullah Nizam, Vanita Motiani, Ritesh George Menezes, Unaiza Naeem, Tariq Jamal Siddiqi, Tehlil Rizwan, Fahd Makhdom, Pradhum Ram, Muhammad Usman · 2021 · Drugs & Aging
  99. Contemporary use of guideline‐based higher potency P2Y12 receptor inhibitor therapy in patients with moderate‐to‐high risk non‐ST‐segment elevation myocardial infarction: Results from the Canadian ACS reflective II cross‐sectional study
    Ashish D. Patel, Shaun G. Goodman, Mary Tan, Neville Suskin, Robert Samuel McKelvie, Andrew L. Mathew, Sohrab R. Lutchmedial, Payam Dehghani, Andrea Lavoie, Thao Thanh Huynh et al. · 2021 · Clinical Cardiology
  100. Personalized antiplatelet therapy: The wrong approach?
    Jean‐Philippe Collet, Gilles Montalescot · 2013 · Archives of cardiovascular diseases